Looking for an antidote to all the payer chest-thumping about cancer drug prices? Here's some news to suit pharma, at least when it comes to cancer immunotherapies. One big distinction in health insurance--between medicines patients take at home and those they receive at doctors' offices--should put a crimp in payers' efforts to squeeze out discounts on PD-1 and PD-L1 therapies.
U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories promise to break out in a big way, and we are not talking just about hepatitis C drugs.
The American Society of Clinical Oncology promised a rating scale for cancer drugs--and now, it has delivered. Let the blowback begin.
No question, immuno-oncology drugs are the hottest tickets in cancer--and among the hottest across the board. But PD-1/PD-L1 treatments, including Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo, aren't the first to bear big sales expectations. How do immuno-oncology forecasts stack up against other notable drug launches?
Pharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response to FiercePharma 's recent coverage is any indication. But the criticism just keeps on coming, even as drugmakers work with payers behind the scenes on mutually acceptable pricing deals.
The buzz about bigger-and-better cancer drug sales abounds at the American Society of Clinical Oncology's annual meeting. But which oncology meds are actually tipped to make major gains between now and the end of the decade?
An Australia government proposal to trim the national drug-coverage budget for innovative drugs by 5%, or U.S.$2.36 billion, has invited a juggernaut of industry opposition already descending on the parliament. The reductions are aimed at the nation's leading drugs, including those for cancer.
A recent analysis by National Institutes of Health researchers found that cancer drug prices aren't exactly linked to drug results. In fact, the study concludes, drugmakers are simply charging "what the market will bear."
England's Cancer Drugs Fund is backtracking in its decision to remove certain treatments from its list of covered drugs, agreeing to keep Novartis' cancer med Afinitor for two of the three indications for which it was supposed to be removed.
Now that Valeant has officially nabbed Dendreon's cancer vaccine Provenge, the Canadian drugmaker will have to nurse the treatment to health.